Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention.
Diabetes mellitus
Gene therapy
Oral hypoglycaemic agents
Stem cells
β-cells regeneration
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
03
09
2018
accepted:
09
10
2018
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
14
5
2019
Statut:
ppublish
Résumé
Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate. Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing. The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure. Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes. Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.
Identifiants
pubmed: 30641727
pii: S1871-4021(18)30418-1
doi: 10.1016/j.dsx.2018.10.008
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-372Informations de copyright
Copyright © 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.